Sugi Predict

Sugi Predict / Targets / MAP4K2

MAP4K2

Mitogen-activated protein kinase kinase kinase kinase 2 · Q12851 · MAP4K2 on Sugi Atlas →

95,357 patent compounds predicted against MAP4K2, 67,315 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL44141 SCHEMBL44141 0.48 5/20
SCHEMBL147381 SCHEMBL147381 0.50 4/20
Linifanib Linifanib (SCHEMBL93804) 1.00 3/20
SCHEMBL143765 SCHEMBL143765 0.82 3/20
SCHEMBL145998 SCHEMBL145998 0.82 3/20
SCHEMBL147845 SCHEMBL147845 0.73 3/20
SCHEMBL142970 SCHEMBL142970 0.72 3/20
SCHEMBL143788 SCHEMBL143788 0.71 3/20
SCHEMBL142448 SCHEMBL142448 0.67 3/20
SCHEMBL146016 SCHEMBL146016 0.64 3/20
SCHEMBL144273 SCHEMBL144273 0.63 3/20
SCHEMBL145151 SCHEMBL145151 0.63 3/20
SCHEMBL144892 SCHEMBL144892 0.61 3/20
SCHEMBL143798 SCHEMBL143798 0.61 3/20
SCHEMBL147370 SCHEMBL147370 0.60 3/20
SCHEMBL150090 SCHEMBL150090 0.60 3/20
SCHEMBL143006 SCHEMBL143006 0.59 3/20
SCHEMBL143225 SCHEMBL143225 0.59 3/20
SCHEMBL68662 SCHEMBL68662 0.58 3/20
SCHEMBL57834 SCHEMBL57834 0.58 3/20

Clinical trials — most relevant to MAP4K2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Molecular Mechanisms of Type 2 Diabetes Mellitus PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva... PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery PHASE2COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Glutamate Supplementation in Young Men nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAP4K2 binder may also engage these)

ProteinNameSimilarity
Q61161 — 1.000 Q61161 →
MAP4K1 Mitogen-activated protein kinase kinase kinase kinase 1 0.995 landscape →
P70218 — 0.990 P70218 →
Q8C6B2 — 0.983 Q8C6B2 →
Q99JP0 — 0.982 Q99JP0 →
Q3UFQ8 — 0.980 Q3UFQ8 →
Q8BYZ7 — 0.979 Q8BYZ7 →
Q8ND23 — 0.979 Q8ND23 →
Q9R011 — 0.978 Q9R011 →
Q9UJ98 — 0.978 Q9UJ98 →
P70268 — 0.978 P70268 →
Q5XHY1 — 0.977 Q5XHY1 →
Q6V7V2 — 0.976 Q6V7V2 →
Q9BUR4 — 0.976 Q9BUR4 →
Q9NY99 — 0.976 Q9NY99 →
Q86UX7 — 0.976 Q86UX7 →
A6QR40 — 0.976 A6QR40 →
Q3TJ91 — 0.975 Q3TJ91 →
Q96MI9 — 0.975 Q96MI9 →
Q9BST9 — 0.975 Q9BST9 →
Q1L8L6 — 0.975 Q1L8L6 →
Q6P1M3 — 0.975 Q6P1M3 →
Q96BJ8 — 0.975 Q96BJ8 →
Q8K045 — 0.974 Q8K045 →
Q8TE68 — 0.974 Q8TE68 →
Q9WV34 — 0.973 Q9WV34 →
Q5VV41 — 0.973 Q5VV41 →
PKN1 Serine/threonine-protein kinase N1 0.973 landscape →
ABHD16A Phosphatidylserine lipase ABHD16A 0.973 landscape →
Q9R0T8 — 0.973 Q9R0T8 →